Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy - retrospective analysis of changes over 3yr in a German hospital

European Journal of Haematology

Volumn 88, Issue 1, 2012, Pages 68-77

  Böhme, Angelika ^a   Atta, Johannes ^a   Mousset, Sabine ^a   Ehlken, Birgit ^b   Shlaen, Margarita ^b   Bug, Gesine ^a   Serve, Hubert ^a   Hoelzer, Dieter ^a  

^a GOETHE UNIVERSITY   (Germany)

^b IQVIA   (United States)

Author keywords

Acute myeloid leukaemia; Antifungal management; Antifungal prophylaxis; Chemotherapy; Costs; Posaconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; IDARUBICIN; ITRACONAZOLE; POSACONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID; SORAFENIB; VALPROIC ACID; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC FEEDING; FEMALE; GERMANY; HEALTH CARE UTILIZATION; HOSPITAL; HOSPITAL COST; HOSPITAL PATIENT; HOSPITAL PERSONNEL; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; COSTS AND COST ANALYSIS; ECHINOCANDINS; FEMALE; GERMANY; HOSPITALS; HUMANS; LENGTH OF STAY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PARENTERAL NUTRITION; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES;

EID: 83655201305     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01704.x     Document Type: Article

References (35)

1. Rüping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008;68:1941-62.
2. Denning DW. Therapeutic outcome in invasive Aspergillosis. Clin Infect Dis 1996;23:608-15.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66.
4. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003;4:974-90.
5. Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009;27:3398-409.
6. Sanz Alonso MA, Jarque Ramos I, Salavert Lleti J, Peman J. Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes. Clin Microbiol Infect 2006;12(Suppl 7):2-6.
7. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive Aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-66.
8. Cornely OA, Bohme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the infectious diseases working party of the German Society for Haematology and Oncology. Haematologica 2009;94:113-22.
9. Caston-Osorio JJ, Rivero A, Torre-Cisneros J. Epidemiology of invasive fungal infection. Int J Antimicrob Agents 2008;32(Suppl 2):S103-9.
10. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009;52:197-205.
11. Frampton JE, Scott LJ. Posaconazole: a review of its use in the prophylaxis of invasive fungal infections. Drugs 2008;68:993-1016.
12. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47.
13. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011;46:709-18.
14. Krueger K, Christie Nelson A. Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies. Clinicoecon Outcomes Res 2009;1:35-43.
15. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26-34.
16. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
17. ®. Rote Liste 2007. Frankfurt/Main: Editio Cantor Verlag, 2007.
18. DKG-NT Band I/BG-T. Tarif der Deutschen Krankenhausgesellschaft. Stuttgart: Kohlhammer, W Verlag GmbH; 2007:31. Auflage.
19. Heil G, Krauter J, Raghavachar A, et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged
20. Schlenk RF, Bommer M, Schmid M, et al. Valproic acid as adjunct to induction therapy in patients with acute myeloid leukemia: first results of two randomized studies of the AMLSG. Blood (ASH Annual Meeting Abstracts) 2005;106:2800.
21. Bug G, Koschmieder S, Krauter J, et al. Priming with granulocyte-colony stimulating factor did not improve outcome in a randomized study of elderly acute myeloid leukemia but increased induction mortality. Blood (ASH Annual Meeting Abstracts) 2006;108:1980.
22. European Medicines Agency. Nexavar: Zusammenfassung der Merkmale des Arzneimittels. 2010 Nov 26.
23. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
24. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL3 - 2009 update. Bone Marrow Transplant 2011;46:709-18.
25. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of Aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60.
26. Hahn-Ast C, Glasmacher A, Muckter S, Schmitz A, Kraemer A, Marklein G, Brossart P, von Lilienfeld-Toal M. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010;65:761-8.
27. Hof H. Mycoses in the elderly. Eur J Clin Microbiol Infect Dis 2010;29:5-13.
28. Chabrol A, Cuzin L, Huguet F, et al. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica 2010;95:996-1003.
29. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, El BA, Steyerberg EW, Rijnders BJ. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008;47:1507-12.
30. Tong KB, Lau CJ, Murtagh K, Layton AJ, Seifeldin R. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis 2009;13:24-36.
31. Kaskel P, Tuschy S, Wagner A, Bannert C, Cornely OA, Glasmacher A, Lipp HP, Ullmann AJ. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol 2008;87:311-9.
32. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51.
33. Nemerovski CW, Mackler ER, DePestel DD, Collins CD, Welch KS, Stevenson JG. Drug costs and utilization after implementation of a posaconazole prophylaxis protocol in adults with acute myelogenous leukemia. Am J Health Syst Pharm 2010;67:295-9.
34. Lyseng-Williamson KA. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. Pharmacoeconomics 2011;29:251-68.
35. Michallet M, Gangneux JP, Lafuma A, Herbrecht R, Ribaud P, Caillot D, Dupont B, Moreau P, Berger P, O'Sullivan AK. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system. J Med Econ 2011;14:28-35.